AI and semiconductor stocks are overvalued and shifting to healthcare stocks like Eli Lilly and Company could be wise. Click ...

Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...

A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...

Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.

The Trump administration is considering a five-year pilot program to cover weight-loss drugs under Medicare and Medicaid, the ...

Markets are assessing the reshaped US trade landscape after Trump on Thursday laid out steep new tariffs for dozens of ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.

Donanemab, approved by the FDA in 2024 to treat Alzheimer's disease, is a monoclonal antibody directed at N-terminally ...

The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially ...

At their peak last year, one share in the company Novo Nordisk cost $142; now, they can be bought for under $50.

Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.